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Abstract
Background: A broad spectrum of pathogens is causative for respiratory tract infections, but symptoms are mostly
similar. Therefore, the identification of the causative viruses and bacteria is only feasible using multiplex PCR or
several monoplex PCR tests in parallel.
Methods: The analytical sensitivity of three multiplex PCR assays, RespiFinder-19, RespiFinder-SMART-22 and
xTAG-Respiratory-Virus-Panel-Fast-Assay (RVP), were compared to monoplex real-time PCR with quantified
standardized control material. All assays include the most common respiratory pathogens.
Results: To compare the analytical sensitivity of the multiplex assays, samples were inoculated with 13 different
quantified viruses in the range of 101 to 105 copies/ml. Concordant results were received for rhinovirus, whereas
the RVP detected influenzavirus, RSV and hMPV more frequently in low concentrations. The RespiFinder-19 and the
RespiFinder-SMART-22 showed a higher analytical sensitivity for adenoviruses and coronaviruses, whereas the RVP
was incapable to detect adenovirus and coronavirus in concentrations of 104 copies/ml. The RespiFinder-19 and
RespiFinder-SMART-22A did not detect influenzaviruses (104 copies/ml) and RSV (103 copies/ml). The detection of all
13 viruses in one sample was only achieved using monoplex PCR. To analyze possible competitive amplification
reactions between the different viruses, samples were further inoculated with only 4 different viruses in one sample.
Compared to the detection of 13 viruses in parallel, only a few differences were found.
The incidence of respiratory viruses was compared in tracheal secretion (TS) samples (n = 100) of mechanically
ventilated patients in winter (n = 50) and summer (n = 50). In winter, respiratory viruses were detected in 32 TS
samples (64%) by RespiFinder-19, whereas the detection rate with RVP was only 22%. The most frequent viruses
were adenovirus (32%) and PIV-2 (20%). Multiple infections were detected in 16 TS samples (32%) by RespiFinder-19.
Fewer infections were found in summer (RespiFinder-19: 20%; RVP: 6%). All positive results were verified using
monoplex PCR.
Conclusions: Multiplex PCR tests have a broad spectrum of pathogens to test at a time. Analysis of multiple
inoculated samples revealed a different focus of the detected virus types by the three assays. Analysis of clinical
samples showed a high concordance of detected viruses by the RespiFinder-19 compared to monoplex tests.
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Background
Acute respiratory tract infections are the most wide-
spread type of infection in adults and children and are
responsible for a considerable morbidity and mortality
worldwide. A high rate of respiratory tract infections is
caused by viruses (approximately 80%) [1,2]. Within the
last ten years, diagnosis of respiratory viruses has be-
come more important, because of the unexpected emer-
gence of several new respiratory viruses: (a) influenza A
virus H5N1 (1997), (b) human metapneumovirus
(hMPV; 2001; [1]), (c) coronavirus SARS (CoV-SARS;
2002); (d) mimivirus (2003; [2]); (e) coronavirus NL63
(CoV-NL63; 2004; [3]); (f ) coronavirus HKU1 (CoV-
HKU1; 2005; [4]), (g) human bocavirus (2005; [5]), (h)
parvovirus 4 (2005; [6]), (i) influenza A virus H1N1
(INF-A; 2009). Due to the similarity in clinical presenta-
tion of respiratory tract infections, causative pathogens
could not be identified on the basis of symptoms alone.
However, an efficient pathogen-based prophylaxis or
therapy has a significant effect on the disease progress in
patients [7,8]. To overcome limitations concerning the
use of several monoplex tests in parallel and the result-
ing shortage of sample volume, the development of
multiplex tests for a fast and exact identification is ne-
cessary. Today, several multiplex tests are commercially
available [9-16]. A number of studies have already com-
pared the detection frequencies of multiplex assays with
conventional monoplexPCR assays in clinical samples
[12,17-19], but a comparison of the analytical sensitivity
of these multiplex assays with quantified standardized
control material does not exist.
This study presents the first comparison of the analyt-
ical sensitivity of three novel multiplex PCR methods,
the RespiFinder-19 assay, RespiFinder-SMART(Single
tube Multiplex Amplification in Real-Time)-22 assay
(both PathoFinder, Maastricht, Netherlands) and the
xTAG Respiratory Virus Panel Fast Assay (Abbott Mo-
lecular, Wiesbaden, Germany), with quantified virus con-
trol material. The RespiFinder-19 assay, which is based
on the multiplex ligation-dependent probe amplification
analyzed by capillary electrophoresis, detects 15 respira-
tory viruses and 4 bacteria in one reaction [20]. A fur-
ther development of the RespiFinder-19 assay is the
RespiFinder-SMART-22 assay, which is also based on
the multiplex ligation-dependent probe amplification.
This assay differentiates 18 respiratory viruses and 4 bac-
teria in one reaction by melt curve analysis. The xTAG
Respiratory Virus Panel Fast Assay (RVP) is a bead
array-based system for the detection of 19 different re-
spiratory viruses [9,10]. Previous studies with clinical
samples showed that the sensitivity and specificity of the
RVP assay was 78.8% and 99.6%, respectively, compared
to real-time PCR-methods, that are currently declared as
the gold standard [21]. Another study performed a
comparison with clinical samples of the RespiFinder-19
with the precursor assay of the RVP [7]. Both assays in
this study have an excellent specificity and the sensitivity
was 33% and 78% for the RVP and the RespiFinder-19
assay, respectively.
The aims of the present study were as follows: (a) the
quantification of commercially available qualitative con-
trol material for (b) the evaluation of the performance
and sensitivity of the three multiplex assays RespiFinder-
19, RespiFinder-SMART-22 and RVP fast assay and (c)
the applicability and performance of these multiplex
PCR assays in a routine setting. Furthermore, this is the
first screening study determining the incidence of infec-
tions with respiratory pathogens in a mechanically venti-
lated patient cohort developing an atypical pneumonia




Tracheal secretion (TS) samples (n=100) were collected in
February (winter, n = 50) and July (summer, n=50) 2010
from mechanically ventilated non-immunocompromised
patients (male: 59%, female: 41%, mean age 62.8 ± 23.2
years, range 23–91). Patients were suspected of atypical
pneumonia during postoperative monitoring after coronary
artery bypass, heart or lung surgery. TS samples were ini-
tially analyzed for bacterial and viral pathogens with our
routine diagnostic profile including CMV, Legionella pneu-
mophila, Pneumocytisjirovecii, Mycoplasma pneumoniae
and Chlamydophilapneumoniae. The residual material was
used for the comparative analysis with the RespiFinder-19
and RVP assay. The results of the performance evaluation
were received retrospectively and had no influence on
patient's therapy. All patients provided informed consent.
For our study we did not need an ethical approval, because
in paragraph }24 of the German Act on Medical Devices
(in German: GesetzueberMedizinprodukte - MPG) an eth-
ical approval is not required for clinical specimens without
a separate invasive sampling.
Virus controls
The qualitative Respiratory Validation Panel Global
(NATRVP-2, ZeptoMetrix Corporation, Buffalo, New
York) was quantified by real-time qPCR. External plasmid
standards were used to determine the concentration of the
different viruses. Plasmid standards of adenovirus (from
position 18895 to 18968, accession number AC_000008),
influenza A virus (from position 144 to 238, accession
number CY041531), RSV-A (from position 1801 to 1949,
accession number M11486), enterovirus (from position
455 to 602, accession number D00820) and rhinovirus
(from position 356 to 563, accession number D00239) were
established [15]. Samples were analyzed in triplicate in
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three independent PCR assays. The viruses hMPV, PIV-1,
PIV-2 and PIV-3 were quantified by LightMix assays (TIB
MOLBIOL, Berlin, Germany).
The virus controls of the NATRVP-2 are purified intact
virus particles that have been chemically modified to ren-
der them non-infectious and refrigerator stable. Quantifi-
cations of viruses included in this panel were as follows:
influenza A virus (H1: 2.31E+05 copies/ml, H3: 1.85E+05
copies/ml), RSV-A (5.12E+05 copies/ml), adenovirus
(4.63E+05 copies/ml), rhinovirus (3.68E+05 copies/ml),
hMPV (2.31E+ 05 copies/ml), PIV-1 (2.09E+05 copies/
ml), PIV-2 (1.19E+ 05 copies/ml) and PIV-3 (4.99E+05
copies/ml) (Table 1).
For the undiluted samples with 13 viruses, 22 μl of each
virus were mixed (total volume: 286 μl). Accordingly, for
the undiluted samples inoculated with 4 viruses, 22 μl of
each virus were mixed and filled up with PBS to achieve
also a final volume of 286 μl. Subsequently, 200 μl of the
sample was extracted using the NucliSENSeasyMAG auto-
mated system with an elution volume of 55 μl.
Nucleic acid extraction
The total nucleic acid from inoculated samples and tra-
cheal secretion samples (TS) was extracted using the
NucliSENSeasyMAG automated system (bioMérieux,
Nürtingen, Germany) according to the manufacturer’s
instructions. Nucleic acids were extracted from 500 μl of
TS samples and 200 μl of inoculated samples and were
eluted in a final volume of 55 μl (routine diagnostic) or
100 μl elution buffer, respectively (bioMérieux, Nürtin-
gen, Germany). The manufacturer of the Respi-Finder-
19 and SMART-22 assays (Pathofinder) recommend an
elution volume of 100 μl, whereas the manufacturer of
the RVP assay recommend an elution volume of 55 μl.
To avoid false negative results due to a deviation from
the manufacturer instructions, we extracted residual ma-
terial and used an elution volume of 100 μl.
xTAG Respiratory Virus Panel Fast Assay (RVP)
The nucleic acid extracts were tested using the RVP assay
(Abbott Molecular, Wiesbaden, Germany) according to the
manufacturer’s instructions. The RVP employs a multiplex
PCR with labelled primers and a single-step hybridization
of PCR products to the fluorescent bead array. The detec-
tion was performed using the xMAP 100 IS instrument
(Luminex Molecular Diagnostics Inc., Toronto, Canada)
and the analysis was performed using TDAS RVP FAST
software (version 2.0, Abbott Molecular).
The RVP simultaneously detects influenza A virus
(subtyped as H1, H3 or H5), influenza B virus, RSV-A
and -B, adenovirus, hMPV, PIV-1, -2, -3 and −4, corona-
viruses 229E, NL63, OC43 and HKU1, picornavirus (en-
terovirus and rhinovirus) and human bocavirus. The
assay also includes an internal positive control added to
each specimen at the extraction step (phage MS2) and a
positive run control that is added to each plate (phage
lambda DNA) [16].
RespiFinder-19 and RespiFinder-SMART-22 assay
The RespiFinder-19 and the RespiFinder-SMART-22 (both
PathoFinder, Maastricht, The Netherlands) were used
according to the manufacturer’s instructions except for the
nucleic acid extraction of patient samples, because we use
500 μl of TS samples instead of 200 μl as recommend. Elu-
tion volumes were used as described previously. Briefly, the
assays comprised a preamplification step, which combines
reverse transcriptase and multiplex target amplification
PCR, followed by a probe hybridization step, a probe
ligation step and a probe amplification step. The
RespiFinder-19 analyzes the amplified PCR products by ca-
pillary electrophoresis using a DNA analyzer (ABI 3730,
Applied Biosystems, Darmstadt, Germany), whereas the
RespiFinder-SMART-22 analyzes by melt curve analysis on
the RotorGene Q (Qiagen, Hilden, Germany).
The RespiFinder-19 simultaneously detects 15 respira-
tory viruses (adenovirus, coronaviruses 229E, NL63,
OC43, hMPV, influenza A virus, influenza A virus H5N1,
influenza B virus, PIV-1, -2, -3 and −4, RSV-A and -B,
rhinovirus) and four bacteria (Bordetella pertussis, Chla-
mydophila pneumoniae, Legionella pneumophila, Myco-
plasma pneumoniae). The RespiFinder-SMART-22
additionally detects coronavirus HKU1, enterovirus and
bocavirus. Both assays also tests an internal positive con-
trol added to each specimen at the extraction stage (RNA
transcript of the polyprotein gene from encephalomyo-
carditis virus) [20].
Monoplex real-time PCR
PCR primers and probes were adapted as previously
described: adenovirus [17], coronavirus (types NL63,
HKU-1, OC43, 229E) [18], cytomegalovirus (CMV) [19],
enterovirus [22], influenza A virus [23], RSV-A [22],
Table 1 Key parameters for monoplex real-time PCR
assays
Virus Dynamic range Efficiency Interassay-
variabilty
R2
INF-A H1 1.00E + 05 - 1.00E + 01 1.89 22.7 ± 0.49 0.972
INF-A H3 1.00E + 05 - 1.00E + 01 1.89 22.7 ± 0.49 0.972
RSV-A 1.00E + 06 - 1.00E + 01 1.98 22.4 ± 0.36 0.998
PIV-1 1.00E + 06 - 1.00E + 01 1.91 29.9 ± 0.84 0.993
PIV-2 1.00E + 05 - 1.00E + 01 1.95 29.3 ± 0.33 0.997
PIV-3 1.00E + 06 - 1.00E + 01 1.88 36.4 ± 0.30 0.989
HRV 1.00E + 06 - 1.00E + 01 1.90 21.3 ± 0.34 0.991
AdV 1.00E + 06 - 1.00E + 01 1.88 19.9 ± 0.17 0.989
hMPV 1.00E + 06 - 1.00E + 01 1.87 26.7 ± 0.66 0.986
*Concentration of viruses are concordant to Table 2.
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rhinovirus [24] and Legionella pneumophila [25]. The
bacteriophage MS2 was used as an internal control (IC)
for the reverse transcription PCR as previously described
[26]. A 89 bp fragment of the bacteriophage lambda (pos-
ition 2402 to 2491, accession number J02459) was used
as IC to avoid competitive co-amplification of DNA
viruses.
RNA amplification of coronavirus (types NL63, HKU-1,
OC43, 229E), influenza A virus, RSV-A and rhinovirus was
carried out in 0.2 ml tubes containing 45 μl reaction mix
and 5 μl RNA extract. The reaction mix consisted of
2× Invitrogen rnx-reaction mix (including 50 mM
MgSO4), 400 nM of target primers, 100 nM of the target
probe, 200 nM of IC primers, 100 nM of the IC probe and
5 U of Invitrogen SuperScript Platinum Taq-enzym mix
(SuperScript III One-Step RT-PCR with Platinum-Taq,
Invitrogen, Darmstadt, Germany). A 203-bp PCR product
of the bacteriophage MS2 replicase gene was added to the
reaction mixture as an exogenous IC. PCR was performed
on the RotorGene Q system (Qiagen, Hilden, Germany)
with a reverse transcription at 50°C for 15 min, preliminary
denaturation at 95°C for 10 min, followed by 45 cycles of
denaturation of 95°C for 15 s, annealing and extension at
60°C for 45 s, with a single fluorescence acquisition step at
the end of the annealing step.
DNA amplification of CMV, adenovirus and entero-
virus was carried out in 0.2 ml tubes containing 45 μl re-
action mix and 5 μl DNA extract. The reaction mix
consisted of 10 ×Taq buffer (including 50 mM Mg), 400
nM of each deoxynucleoside triphosphate, 500 nM of
target primers, 200 nM of the target probe, 300 nM of
IC primers, 100 nM of the IC probe, 0.01 U of Uracil-
DNA Glycosylase (UNG, Roche Diagnostics, Mannheim,
Germany) and 5 U of Taq DNA polymerase (5 PRIME,
Hamburg, Germany). PCR was performed on the
Rotor-Gene 3000 system (Corbett Life Sciences, Sydney,
Australia) with an UNG activity step at 37°C for 5 min,
preliminary denaturation at 95°C for 10 min, followed by
45 cycles of denaturation of 95°C for 15 s, annealing and
extension at 65°C for 45 s, with a single fluorescence
acquisition step at the end of the annealing step.
The Legionella pneumophila PCR was carried out in
glass capillaries containing 15 μl reaction mix and 5 μl
DNA extract. The reaction mix consisted of 5 × FastStart
DNA Master Plus Hybridization Probes (Roche Diagnos-
tics, Mannheim, Germany), 200 nM of each target pri-
mer, 150 nM of the target probe, 300 nM of each IC
primer for lambda, 100 nM of the IC probe and 0.01 U
of UNG (Roche Diagnostics, Mannheim, Germany). PCR
was performed on the LightCycler 2.0 system (Roche
Diagnostics, Mannheim, Germany) with an UNG activity
step at 37°C for 10 min, preliminary denaturation at 95°C
for 10 min, followed by 45 cycles of denaturation of 95°C
for 2 s, annealing at 55°C for 10 s and extension at 72°C
for 15 s, with a single fluorescence acquisition step at the
end of the annealing step, and a following melt analysis
(95°C for 60 s and 40°C for 30 s).
The real-time PCR for hMPV, PIV-1, -2 and −3 was per-
formed using LightMix assays (TIB MOLBIOL, Berlin,
Germany) on the LightCycler 2.0 system according to the
manufacturer’s instructions.
The cut-off value for the decision positive/negative
was adjusted to <40 cycles. The specificity of all
monoplex-real-time PCR assays was determined by the
exclusion of cross-amplification with different bacterial
or viral DNAs/RNAs (eight bacteria, seven viruses). The
analytical sensitivity was determined to be <10 copies/
ml. The reproducibility of the assay was demonstrated
by analyzing the inter-assay variation for the crossing
threshold (CT) values, determined from six independent
PCR runs. Key parameters for real-time PCR assays are
shown in Table 1.
Results
Comparison of xTAG Respiratory Virus Panel Fast assay
(RVP) with RespiFinder-19 assay and RespiFinder-SMART-
22 assay using virus control material
Virus control material, NATRVP2 (Zeptometrix), was
quantified by external plasmid standards for a compari-
son of the analytical sensitivity of the RVP, RespiFinder-
19 and RespiFinder-SMART-22 assays. Subsequently,
PBS-buffer was inoculated with 13 different quantified
viruses, or 4 viruses in different combinations, in the
range of 101-104 copies/ml. Nucleic acid extracts were
analyzed in parallel with the three multiplex methods
and monoplex real-time PCR methods (elution volume
55 μl). The RVP showed the detection of influenzavirus
A (INF-A, 1.78E + 02 copies/ml), respiratory syntical
virus A and B (RSV-A/B, 3.94E + 02 copies/ml), corona-
virus OC43 (CoV OC43) and human metapneumovirus
(hMPV, 1.78E + 01 copies/ml) even in a high dilution
ratio (Table 2). Rhinovirus (HRV) was also detected in
low concentration by RVP; however this assay is not able
to differentiate between human rhinovirus and entero-
virus due to the high sequence similarity (manufacturer’s
information). INF-B, CoV 229E, parainfluenzavirus 1–3
(PIV-1-3) and adenovirus (AdV) were not detected. In
contrast, the RespiFinder-19 and the RespiFinder-
SMART-22 detected AdV and CoV OC43 and 229E also
at low concentrations (e.g. AdV 3.56E + 02). However,
both assay did not detect INF-A or -B, RSV-A or B, PIV-
1 and −3 as well as hMPV in concentrations in the range
of 104 copies/ml. Only the RespiFinder-SMART-22
detected PIV-2 at a concentration of 92 copies/ml).
None of the three multiplex assays was capable of
detecting all 13 viruses in parallel. This was only
achieved using monoplex real-time PCR assay. CT values
were shown in Table 2.
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In order to simulate clinical-relevant multiple infections
as well as to analyse possible competitive amplification
reactions between the different viruses, PBS-buffer was
further inoculated with only 4 different viruses in one
assay (Table 3). The nucleic acid extraction was done
with two different elution volumes, 55 μl (according to
Abbott Molecular instructions) and 100 μl (according
to PathoFinder instructions), to avoid false negative
results due to a deviation from the manufacturer
instructions. We tested different viruses in three com-
binations (Panel 1: INF-A H1N1, RSV-A, HRV and
AdV; Panel 2: INF-A H1N1, INF-A H3N2, RSV-A,
PIV-2; Panel 3: CoV OC43, CoV 229E, AdV and HRV).
Compared to the detection of 13 viruses in parallel,
Table 2 Comparison of RVP, RespiFinder-19, RespiFinder-SMART-22 and monoplex real-time PCR with regard to the
analytical sensitivity in a sample with 13 viruses
Virus Concentration
[copies/ml]
RVP RespiFinder-19 RespiFinder- SMART-22 Monoplex real-time PCR
und. 1:10 1:100 1:1000 und. 1:10 1:100 1:1000 und. 1:10 1:100 1:1000 und. 1:10 1:100 1:1000
INF-A H1 1.78E+04 + + + - - - - - - - - - 32.9 33.8 35.8 37.9
INF-A H3 1.42E+04 + + + - - - - - - - - -
INF-B n. q. - - - - - - - - - - - - x x x x
RSV-A 3.94E+04 + + + - - - - - - - - - 28.7 30.4 32.5 34.6
RSV-B n. q. + + + - - - - - - - - - x x x x
PIV-1 1.61E+04 - - - - - - - - - - - - 32.8 33.1 34.9 36.6
PIV-2 9.19E+03 - - - - + - - - + + + - 29.5 31.4 33.7 36.4
PIV-3 3.84E+04 - - - - - - - - - - - - 34.9 36.8 38.3 39.8
CoV OC43 n. q. + + + + + + + + + + + + 27.6 28.9 30.1 31.9
CoV 229E n. q. - - - - + + + + + + + + 26.8 27.9 29.1 30.5
HRV 2.83E+04 + + + + + + - - + + + - 31.2 33.8 36.0 38.4
AdV 3.56E+04 - - - - + + + + + + + - 35.9 37.6 38.8 39.9
hMPV 1.78E+04 + + + + - - - - - - - - 30.2 32.0 34.8 38.4
n. q.: not quantified; x: not performed; und.: undiluted; The dilution series were done as two-fold dilution series.
Table 3 Comparison of RVP, RespiFinder-19, RespiFinder-SMART-22 and monoplex real-time PCR with regard to the
analytical sensitivity in a sample inoculated with 4 viruses
RVP RespiFinder-19 RespiFinder-SMART-22 Monoplex real-time PCR (CT)
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only a few differences were found using the same elution
volume of 55 μL. RSV-A and AdV were now detected by
the RespiFinder-19 and RespiFinder-SMART-22 assays at
concentrations ranging from 104 copies/ml (panel 1) to
102 copies/ml (RSV panel 2, AdV panel 3). The RVP assay
now detect AdV (104 copies/ml panel 1, 103 copies/ml
panel 3) and PIV-2 (104 copies/ml, panel 2). The RVP was
still incapable of detecting CoV 229E. However, more dif-
ferences were found in the detection of the pathogens
using different elution volumes for both RespiFinder
assays. The company PathoFinder suggests an elution vol-
ume of 100 μl for the RespiFinder-19 and the RespiFinder-
SMART-22 assay, whereas Abbott Molecular advises for
the RVP assay an elution volume of 55 μl. The two assays
of the company PathoFinder did not detect INF-A in sam-
ples which were extracted in 55 μl elution buffer, but de-
tection was possible by using the advised extraction
volume of 100 μl. The RespiFinder-19 detect INF-A at a
concentration of 104 copies/ml (panel 1), whereas both
assays detect INF-A at concentrations ranging from 102
-104 copies/ml (panel 2). The same observation was made
for the detection of AdV at a concentration of 102 copies/
ml (panel 1) with the RespiFinderSMART-22 by using the
advised extraction volume of 100 μl. In contrast, the de-
tection frequency of RSV-A virus was reduced for both
RespiFinder assays analysing samples with 100 μl elution
volume compared to 55 μl elution volume (panel 1: un-
diluted sample; panel 2: RespiFinder19 all samples,
RespiFinderSMART-22 dilution 1:100). No differences in
the detection frequency were found for the RVP assay
(Table 3).
Detection of respiratory viruses in clinical samples
Additionally, we evaluated the applicability of the RVP
and the RespiFinder-19 for routine diagnosis and the
distribution of viruses in our patient cohort in 100 TS
samples during winter (February) and summer (July).
The RespiFinder-SMART-22 as a further development of
the RespiFinder-19 was not participating in this study,
because it started before the RespiFinder-SMART-22
was commercially available. All positive results were
verified with real-time PCR as monoplex analysis. TS
samples were obtained routinely from mechanically ven-
tilated patients after coronary artery bypass, heart or
lung surgery who were suspected of atypical pneumonia
during post-operative monitoring.
Respiratory viruses were detected by RespiFinder-19 in
32 TS samples from winter (64%) (Figure 1). The most
frequent viruses were AdV, which was found in 16 TS
samples (32%), and PIV-2, which was found in 10 TS
samples (20%). Other detected viruses were CoV 229E
(10%), PIV-3 (6%), HRV (6%), INF-B (4%), RSV-A (4%),
INF-A (2%) and hMPV (2%). In comparison, the RVP
detected respiratory viruses only in 11 TS samples
(22%). Rhinovirus, which was found in 4 TS samples
(8%), was the most frequent virus in addition to CoV
229E (4%), CoV HKU1 (2%), AdV (2%), PIV-3 (2%),
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Figure 1 Comparison of RVP, RespiFinder-19, and real-time PCR results for TS samples in winter and summer. The rectangular boxes
symbolize the different assays. * L. pneumophila is not in the spectrum of pathogens of the RVP and CoV HKU1 is not in the spectrum of the
RespiFinder-19.
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respiratory virus infections were found in the TS sam-
ples by the different assays. The RespiFinder-19 detected
in 10 TS samples (20%) respiratory viruses in contrast to
the RVP, which found viruses only in 3 TS samples (6%),
respectively (Figure 1). Furthermore, the spectrum of
detected viruses was smaller in summer: AdV (10%),
HRV (8%) and PIV-2 (both 2%). Additionally, L. pneu-
mophila was detected by the RespiFinder-19 (2%). In
order to confirm positive results obtained by RVP and
RespiFinder, samples were additionally tested by mono-
plex real-time PCR with 100% concordance (Figure 1).
The analyses of three TS samples with RVP failed
(Table 4). The error message “Sample failure in saline
due to unexpected control call” appeared. The manufac-
turer provided the information that this is possible, if
the sample is positive for a pathogen which is not in the
spectrum of pathogens of the kit. In these three cases
the samples contained CMV (detection only with mono-
plex real-time). In order to exclude CMV pneumonia
due to reactivation processes, samples had already been
tested for CMV in line with our standard diagnostic pro-
file, and data was provided for completeness.
In 16 TS samples (32%) from February, multiple infec-
tions were detected (Table 4). One triple infection with
INF-B, PIV-2 and CMV was found. Double infections with
adenovirus and PIV-2 (8%) as well as adenovirus and CMV
(6%) were the most frequent combination. In July, double
infections were only detected in 2 TS samples (4%). The
detection of multiple infections was only possible with
RespiFinder-19. The highest detection rate of 43 viruses in
all samples was reached with the RespiFinder-19. A con-
firmation reaction was performed with monoplex PCR
assay, which found a total of 45 viruses in 100 TS samples.
The viruses which were only detected with RespiFinder-19
showed high cycle threshold points in monoplex PCR
methods due to low virus concentrations.
Discussion
The detection of respiratory viruses by multiplex PCR
has been described as an important tool for the identifi-
cation of the pathogens in respiratory tract infections.
But until today no comparison of these three multiplex
PCR methods with quantified standardized virus control
material was performed. Therefore, we quantified virus
control material to compare the analytical sensitivity of
three commercially available multiplex PCR methods,
followed by evaluation of application for routine diagno-
sis with regard to hands-on-time, time-to-result, costs
and accomplishment (Table 5).
We observed that the RVP, the RespiFinder-19 and the
RespiFinder-SMART-22 assay had a different focus of
the detected virus types in the inoculated samples. The
RVP showed an advanced detection of INF-A, RSV, and
hMPV, whereas the RespiFinder-19 and the RespiFinder-
SMART-22 showed an improved detection of CoV 229E
and AdV. The RespiFinder-SMART-22 further showed
an improved detection of PIV-2. Viruses were detected
also at low concentrations of 101-102 copies/ml. CoV
OC43 and HRV were detected equally also at low con-
centrations with the three assays, whereas PIV-1 and
PIV-3 were not detected at all. The parallel analysis with
monoplex real-time PCR assays showed as expected the
highest analytical sensitivity: all viruses were detected in
all concentrations and dilution factors.
Our results indicated a possible competition for
nucleotides, primer or enzymes between the different
viruses in the detection of a high number of multiple
infections (13 viruses in one assay). 13 viruses in one
sample was the maximum demand on the multiplex
PCR tests. This highly artificial experiment emphasizes
the general methodological limitation of multiplex PCR
assay, because nearly all multiplex assays performed ter-
ribly analyzing samples with a high number of parallel
pathogens. Therefore, these results have to be inter-
preted with attention. In the routine clinical setting, a
parallel infection with this high number of different
viruses is uncommon up to impossible, and the clinical
relevance of these results is initially arguable. The high-
est virus load in our patient cohort was a triple infection.
This was also observed by other research groups [8].
Due to this fact we tested three different combinations
of quadruple infections. Surprisingly, only a few differ-
ences were found compared to the highly artificial ex-
periment with 13 viruses. Potential competitive reactions
were found for the detection of RSV and AdV (RespiFin-
der) or INF-A, AdV and PIV-2 (RVP). However, some
viruses were still not detected (e.g. RVP: CoV 229E,
RespiFinder: INF-A). But we observed an influence of
the elution volumes for the detection with the
RespiFinder-19 and the RespiFinder-SMART-22. An elu-
tion volume of 100 μl showed the tendency of a higher
analytical sensitivity. However, the elution volume seems
to have differing influences depending on the contained
viruses. For example, INF-A was detected more frequent
in an elution volume of 100 μl, whereas RSV showed a
higher detection frequency using an elution volume of
55 μl. No differences were found in the detection with the
RVP assay, although we expected that the dilution of the
DNA/RNA extract may result in a reduced analytical sen-
sitivity. For routine testing using this different multiplex
assays in parallel, we suggest an elution volume of 100 μl,
because the remaining extract is available for retesting or
analysis for non-included pathogens. If only one multiplex
assay will be implemented, elution should be performed
according to the specifications of the manufacturer.
The analysis of 100 TS samples was done in parallel
with the RVP and the RespiFinder-19. At that time, the
RespiFinder-SMART-22 was not commercially available
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and later on, no residual extracted material was available
for additional testing. For a comparison of the three
multiplex assays with clinical samples further studies
have to be done. This study indicated a higher clinical
sensitivity of the RespiFinder-19 in the detection of virus
infections in clinical samples with low concentrations in
contrast to the RVP. Respiratory tract infections were
found in 64% of the TS samples by RespiFinder-19. The
RVP detected only 22% in the same samples, respect-
ively. Gadsby et al. [21] also described problems in the
detection of low virus concentrations with RVP; either
the pathogens were not detected or they produced a
false-positive for adenovirus. Raymaekers et al. [7] inves-
tigated clinical samples for a comparison of the
RespiFinder-19 with the precursor assay of the RVP
(xTAG Respiratory Viral Panel Assay, Abbott Molecular,
Wiesbaden, Germany). The precursor assay of the RVP
included a target specific primer extension (TSPE) in
contrast to the new assay, therefore these results are not
directly comparable to the present study. In Raymaekers’
study, respiratory viruses were detected by RVP in 31 of
95 clinical samples and by RespiFinder-19 in 75 of 95.
These results are comparable to our results and verified
our results in present study. A comparison of the pre-
cursor assay of the RVP with the newer RVP assay was
made by Pabbaraju et al. [9]. They showed that the older
assay was more sensitive than the newer RVP Fast assay
(88.6% and 77.5% sensitivities, respectively) for all the
viral targets combined. This corresponds to our observa-
tions concerning the RespiFinder-19. However, the
higher sensitivity of the RespiFinder-19 assay may also
be due to the detection of incidental but non-causal
viruses. In 32% of the February TS samples the
RespiFinder-19 assay detected multiple infections, corre-
sponding to results of Fox [10], whereas the RVP assay
detected no multiple infections. Raymaekers et al. also
described problems in the detection of co-infections
Table 4 Patient samples with positive pathogen detection
from winter and summer
Patient Sex Age (yr) RVP RespiFinder-19 real-time PCR
winter
triple infections
1 m 71 - INF-B, PIV-2 INF-B, PIV-2, CMV
double infections
2 m 52 RSV RSV-A, CoV 229E RSV-A, CoV 229E
3 m 39 CoV 229E CoV 229E CoV 229E, CMV
4 f 84 CoV HKU1 CoV 229E, AdV CoV HKU1, AdV
5 m 59 - PIV-2 PIV-2, CMV
6 f 84 x AdV AdV, CMV
7 m 56 - PIV-2 PIV-2, CMV
8 m 61 - PIV-2, AdV PIV-2, AdV
9 f 23 - PIV-2, AdV PIV-2, AdV
10 f 84 - AdV AdV, CMV
11 f 83 - PIV-2, RSV-A PIV-2, RSV-A
12 m 85 - PIV-2, AdV PIV-2, AdV
13 m 79 - AdV, PIV-3 AdV, PIV-3
14 f 76 - PIV-2, AdV PIV-2, AdV
15 m 56 - AdV, PIV-3 AdV, PIV-3
16 m 71 x AdV AdV, CMV
17 m 74 - INF-A, PIV-2 INF-A, PIV-2
mono infections
18 f 84 AdV AdV AdV
19 f 80 hMPV hMPV hMPV
20 m 65 PIV-3 PIV-3 PIV-3
21 m 73 - AdV AdV
22 m 70 - AdV AdV
23 m 79 - PIV-2 PIV-2
24 f 62 - AdV AdV
25 f 72 HRV HRV HRV
26 f 82 HRV HRV HRV
27 m 80 - AdV AdV
28 m 71 CoV 229E CoV 229E n. d.
29 m 64 - AdV AdV
30 m 58 - AdV AdV
31 f 46 HRV - HRV
32 f 75 HRV HRV HRV
33 m 52 - INF-B INF-B
summer
double infections
34 f 74 HRV HRV HRV, CMV
35 m 70 x AdV AdV, CMV
mono infections
36 m 59 HRV - HRV
Table 4 Patient samples with positive pathogen detection
from winter and summer (Continued)
37 f 77 - - CMV
38 f 78 - - CMV
39 m 81 - - CMV
40 f 43 - HRV HRV
41 m 73 - AdV AdV
42 f 91 HRV HRV HRV
43 m 66 - PIV-2 PIV-2
44 m 59 - AdV AdV
45 f 65 - AdV AdV
46 f 48 - L. pneumophila L. pneumophila
47 m 66 - AdV AdV
f: female; m: male; x: sample failure in Saline due to unexpected control call.
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with the RVP. Samples which include adenovirus and
coronavirus were false-negative with the RVP. We
observed these problems in samples, which were positive
for CMV and adenovirus. The importance of viral co-
infections remains uncertain [11-13]. In summary, we
detected multiple infections in 36% of the TS samples
analyzed and the detection of multiple infections was
only possible using the RespiFinder-19 assay. However,
other studies also demonstrated the detection of mul-
tiple infections using the RVP assay [9,21]. In this con-
text, the question arises, whether all detected viruses in
multiple infections are clinically relevant or not. In some
cases the pathogens of the co-infections cause more
serious illnesses, e.g. coronavirus, RSV or hMPV, than
the pathogens of the primary infection, e.g. rhinovirus.
With this study approach, none of the three assays can
differentiate between pathogens of the primary infection
and the co-infecting virus. Therefore, the clinical rele-
vance of additionally detected viruses has to be corre-
lated in further studies.
The interpretation of the generated data of the three
assays has different levels of difficulty. Abbott Molecular
supplies with the RVP a software tool (TDAS RVP FAST
software), which analyze the generated data and pro-
vided automatically a positive or negative signal for the
detection of the particular virus. The interpretation of
Table 5 Comparison of RVP, RespiFinder-19 and RespiFinder-SMART-22 with regard to test specifications, performance,
cost and accomplishment
RVP RespiFinder-19 RespiFinder-SMART-22
Manufacturer Abbott Molecular PathoFinder PathoFinder
CE IVD/FDA yes/yes yes/no yes/no
TEST SPECIFICATIONS




PIV-1, -2, -3, -4 PIV-1, -2, -3, -4 PIV-1, -2, -3, -4




- B. pertussis B. pertussis
- C. pneumoniae C. pneumoniae
– L. pneumophilaM. pneumoniae L. pneumophilaM. pneumoniae
Sample volume 500 μL 200 μL 200 μL
Elution volume 55 μL 100 μL 100 μL
PCR volume 10 μL 10 μL 10 μL
Principle of detection fluorescence bead array capillary electrophoresis melt curve analysis
PERFORMANCE
Hands-on-time 0.80 h 1.75 h 1.25 h
Time-to-result 3.5 h 7.5 h 6.0 h
COSTS
Costs reagents *,1 90-100 € 50-60 € 50-60 €
Costs equipment * 57-69,000 € 100-120,000 € 33-40,000 €
ACCOMPLISHMENT
Handling + + ++
Personal training duration/qualification 2 d/very low 2 d/very low2 2 d/low






*All prices are for Germany (list price).
1Prices for one sample.
2The personal training will be very low, if technicians are familiar with sequencing using an ABI system.
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the results of the RespiFinder-19 is more difficult, be-
cause the manufacture did not provide helping data for
the analysis (e.g. threshold). So it is possible that low
positive samples were missed. The further developed
RespiFinder-SMART-22, has an improved analysis of the
generated data with given melting points.
In general, the comparison of the spectrum of patho-
gens detected in our patient cohort of mechanically ven-
tilated patients with other studies (e.g. [14]) is hardly
realizable, because the comparability is limited by re-
gional, seasonal and methodological differences. In this
context, the development of a respiratory networks (e.g.
www.medical-dpc.com/respvir) will allow a constant
comparison of seasonal accumulations and chronological
trends.
For the application of the three multiplex PCR meth-
ods in a routine diagnostic setting, the hands-on-time,
the time-to-result, the costs and the accomplishment are
also very important parameters. Table 5 summarizes the
specifications of RespiFinder-19, RespiFinder-SMART-22
and RVP. The time-to-result differs from three and a
half hours with RVP to eight hours with RespiFinder-19.
The RespiFinder-19 also needs more hands-on-time
steps than the RVP. The RespiFinder-SMART-22, as a
further development of the RespiFinder-19, delivers a re-
sult after six hours. This amounts to a time saving of
one and a half hour. For a significant effect on disease
progress, patients with respiratory tract infections need
an efficient pathogen based prophylaxis or therapy.
Multiplex PCR methods allow a fast and exact identifica-
tion of the causative pathogens. For routine application
the analytical sensitivity must balance out the time-to-
result. In our opinion, the turn-around-times of the
RespiFinder-SMART-22 and RVP assay did not have a
significant impact on patient treatment, because both
assays provided results within one working day. In this
context, the RespiFinder-19 demands for a strict time
management to achieve results within a day.
Study limitations: Unless samples were not analyzed in
an adequate number of replicates to perform statistical
analysis, our approach allow the comparison of the per-
formance and the range of sensitivity of the three multi-
plex assays by analysis of inoculated samples with
quantified virus material. Reported differences may be
due to chance regarding a single consideration of indi-
vidual results, however a tendency towards difference in
lower or higher detection efficiencies by the different
assays is observable.
Conclusions
In conclusion, our study shows that before a multiplex
PCR method is applied in routine diagnostics it has to
balance out the analytical sensitivity between time-to-re-
sult, hands-on-time and the clinical relevance of the
detected pathogens. The RespiFinder-19 has a higher
analytical sensitivity than the RVP, but needs more than
twice as long for a result compared to the RVP. The
RespiFinder-SMART-22, as a further development pro-
vides a faster result, but has to been tested with routine
samples in further studies.
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